FDA Orange Book · active-ingredient family
Maraviroc
Maraviroc is approved as 2 brand and 4 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:SELZENTRY · NDA 208984
2
Brand (NDA)
4
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Brand (NDA) products · solution, tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| SELZENTRYRLD | VIIV HLTHCARE | NDA 208984 | — | Nov 04, 2016 | |
| SELZENTRYRLD×4 | VIIV HLTHCARE | NDA 022128 | — | Nov 04, 2016 |
Generic (ANDA) products (4)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| MARAVIROC×2 | RHODES PHARMS | ANDA 216143 | — | Nov 04, 2025 | |
| MARAVIROC×2 | NAVINTA LLC | ANDA 217880 | AB | May 13, 2025 | |
| MARAVIROC×2 | I 3 PHARMS | ANDA 217114 | AB | Aug 17, 2023 | |
| MARAVIROC×2 | HETERO LABS LTD III | ANDA 203347 | AB | Feb 07, 2022 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Maraviroc — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
